# Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

> **NCT00485953** · PHASE4 · COMPLETED · sponsor: **Susan L. Greenspan** · enrollment: 109 (actual)

## Conditions studied

- Bone Loss
- Osteoporosis
- Breast Cancer

## Interventions

- **DRUG:** risedronate

## Key facts

- **NCT ID:** NCT00485953
- **Lead sponsor:** Susan L. Greenspan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2017-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485953, "Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00485953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*